Investigational drug · Phase 2
LP-005
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "LP-005"
First trial start
2024
Nov 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LP-005", any sponsor or status.
Conditions studied
As listed on its trial records.
- Periodontitis
- Paroxysmal Nocturnal Hemoglobinuria
- Complement-mediated Renal Diseases
- PNH - Paroxysmal Nocturnal Hemoglobinuria
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "LP-005" as an intervention, largest first.
- Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe PeriodontitisPivotal-lookingNot yet recruiting
Longbio Pharma (Suzhou) Co., Ltd.Industry
NCT07603713 · 100 participants (planned) · Start May 1, 2026 · Primary completion Nov 12, 2026
Drug: LP-005 Injection; Placebo Injection · For: Periodontitis
Sites: Beijing, China
Longbio PharmaIndustry
NCT06294301 · 68 participants · Start Nov 23, 2023 · Primary completion Aug 31, 2024
Drug: LP-005 Dose 1 (Single); LP-005 Dose 2 (Single) and 9 more · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Shanghai, China
- Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney DiseaseNot yet recruiting
Longbio PharmaIndustry
NCT07363265 · 46 participants (planned) · Start Feb 2, 2026 · Primary completion Aug 2, 2028
Drug: LP-005 Injection · For: Complement-mediated Renal Diseases
Sites: Beijing, China
- Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.Active, not recruiting
Longbio PharmaIndustry
NCT07212426 · 30 participants · Start Nov 14, 2024 · Primary completion May 6, 2026
Drug: LP-005 Injection · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Nanjing, China
- Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruiting
Longbio PharmaIndustry
NCT07266155 · 30 participants (planned) · Start Dec 5, 2025 · Primary completion Dec 30, 2027
Drug: LP-005 Injection · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.